ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 43 filers reported holding ONCOMED PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $0 | -100.0% | 15 | -99.6% | 0.00% | – |
| Q3 2018 | $8,000 | -82.6% | 3,948 | -80.6% | 0.00% | – |
| Q2 2018 | $46,000 | +12.2% | 20,302 | +55.5% | 0.00% | -100.0% |
| Q1 2018 | $41,000 | +173.3% | 13,059 | +279.2% | 0.00% | +100.0% |
| Q3 2017 | $15,000 | -34.8% | 3,444 | -51.0% | 0.00% | 0.0% |
| Q2 2017 | $23,000 | -93.3% | 7,034 | -81.2% | 0.00% | -93.3% |
| Q1 2017 | $344,000 | +158.6% | 37,436 | +116.6% | 0.02% | +87.5% |
| Q4 2016 | $133,000 | -52.8% | 17,285 | -30.0% | 0.01% | -57.9% |
| Q3 2016 | $282,000 | +623.1% | 24,677 | +674.1% | 0.02% | +533.3% |
| Q2 2016 | $39,000 | +105.3% | 3,188 | +68.6% | 0.00% | +50.0% |
| Q1 2016 | $19,000 | -91.6% | 1,891 | -81.1% | 0.00% | -88.9% |
| Q4 2015 | $225,000 | +192.2% | 10,019 | +113.9% | 0.02% | +200.0% |
| Q3 2015 | $77,000 | -43.8% | 4,683 | -23.6% | 0.01% | -45.5% |
| Q2 2015 | $137,000 | – | 6,131 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,042,989 | $8,571,000 | 0.75% |
| NEXTHERA CAPITAL LP | 634,715 | $1,346,000 | 0.26% |
| Endurant Capital Management LP | 219,114 | $465,000 | 0.21% |
| Birchview Capital, LP | 118,689 | $252,000 | 0.16% |
| Perceptive Advisors | 2,620,897 | $5,556,000 | 0.15% |
| Alambic Investment Management, L.P. | 53,972 | $114,000 | 0.09% |
| Sofinnova Investments, Inc. | 395,744 | $839,000 | 0.08% |
| Kazazian Asset Management, LLC | 31,475 | $67,000 | 0.06% |
| Broadfin Capital, LLC | 200,000 | $424,000 | 0.06% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 96,639 | $205,000 | 0.02% |